Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Oncogenic ASPP2κ: A novel regulator of drug resistance and tumor progression in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

RHReka A. HarasztiCDChristoph Driessen

Discussion

Loading...

Member takes

Overview

Findings reveal ASPP2κ drives drug resistance and tumor progression in multiple myeloma, suggesting it as a potential therapeutic target.

Key Points

  • This research aims to explore the role of ASPP2κ in drug resistance and tumor progression in multiple myeloma.
  • Evaluated ASPP2κ expression levels in MM patients and healthy donors
  • Developed isoform-specific shRNA-based cell models to assess proliferation and apoptosis
  • Utilized an NSG xenotransplant model to study tumor engraftment and survival
  • ASPP2κ is overexpressed in multiple myeloma and correlates with adverse survival
  • Knockdown of ASPP2κ reduces proliferation rates by 30-40% and increases apoptosis rates by 30%
  • Inhibition of ASPP2κ enhances sensitivity of MM cells to melphalan and bortezomib by 25%

Cite This Study

Haraszti et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d668https://doi.org/10.1182/blood-2025-5729
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 5992: Expression of oncogenic ASSP2k in acute myeloid leukemia directly contributes to resistance to therapy and aggressiveness of the disease2024
  2. 2Abstract 6149: Oncogenic ASPP2 <i>kappa</i> exerts a regulatory role within the tumor microenvironment and promotes metastasis in TNBC models2026
  3. 3Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma2025 · 1 citations
  4. 4Abstract 3345: PP1 phosphatase complex at the hub of the integrated stress response: A potential therapeutic target in multiple myeloma2024
  5. 5KPNA2 enhances autophagy through activation of the non-canonical NF-κB signaling pathway, thereby promoting the induction of bortezomib resistance in multiple myeloma2025